Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/124228
Title: | Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma |
Author: | Younes, Anas Salles, Gilles Martinelli, Giovanni Bociek, Robert Gregory Caballero, Dolores González Barca, Eva Turgut, Mehmet Gerecitano, John Kong, Oliver Babanrao Pisal, Chaitali Tavorath, Ranjana Seog Kim, Won |
Keywords: | Malaltia de Hodgkin Hodgkin's disease |
Issue Date: | 1-Dec-2017 |
Publisher: | Ferrata Storti Foundation |
Abstract: | Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or refractory non-Hodgkin lymphoma. Three separate cohorts of patients (with diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular lymphoma) received buparlisib 100 mg once daily until progression, intolerance, or withdrawal of consent. The primary endpoint was overall response rate based on a 6-month best overall response by cohort; secondary endpoints included progression-free survival, duration of response, overall survival, safety, and tolerability. Overall, 72 patients (26 with diffuse large B-cell lymphoma, 22 with mantle cell lymphoma, and 24 with follicular lymphoma) were treated. The overall response rates were 11.5%, 22.7%, and 25.0% in patients with diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma, respectively; two patients (one each with diffuse large B-cell lymphoma and mantle cell lymphoma) achieved a complete response. The most frequently reported (>20%) adverse events of any grade in the population in which safety was studied were hyperglycemia, fatigue, and nausea (36.1% each), depression (29.2%), diarrhea (27.8%), and anxiety (25.0%). The most common grade 3/4 adverse events included hyperglycemia (11.1%) and neutropenia (5.6%). Buparlisib showed activity in relapsed or refractory non-Hodgkin lymphoma, with disease stabilization and sustained tumor burden reduction in some patients, and acceptable toxicity. Development of mechanism-based combination regimens with buparlisib is warranted. |
Note: | Reproducció del document publicat a: https://doi.org/10.3324/haematol.2017.169656 |
It is part of: | Haematologica, 2017, vol. 102, num. 12, p. 2104-2112 |
URI: | http://hdl.handle.net/2445/124228 |
Related resource: | https://doi.org/10.3324/haematol.2017.169656 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
YounesA.pdf | 1.14 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License